Cargando…

Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data

SUMMARY: Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be causing time-varying confounding. BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model versus the weig...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, F., Goli, V., Petraro, P., McMullan, T., Sprafka, J. M., Tchetgen Tchetgen, E. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624978/
https://www.ncbi.nlm.nih.gov/pubmed/28685279
http://dx.doi.org/10.1007/s00198-017-4129-6
_version_ 1783268325962285056
author Xue, F.
Goli, V.
Petraro, P.
McMullan, T.
Sprafka, J. M.
Tchetgen Tchetgen, E. J.
author_facet Xue, F.
Goli, V.
Petraro, P.
McMullan, T.
Sprafka, J. M.
Tchetgen Tchetgen, E. J.
author_sort Xue, F.
collection PubMed
description SUMMARY: Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be causing time-varying confounding. BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model versus the weighted MSM. The discrepancy of effect estimates for overall infection in the MSM suggested there may be time-varying confounding. INTRODUCTION: Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be affected by prior treatment and confound the subsequent treatment effect, causing time-varying confounding. METHODS: In a US insurance database, the association between joint treatment of bisphosphonates (BP) and other OP medication and the incidence of infections among postmenopausal women was assessed using a marginal structural model (MSM). Stabilized weights were estimated by modeling treatment and censoring processes conditioning on past treatment, and baseline and time-varying covariates. RESULTS: BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model {incidence rate ratio [IRR] [95% confidence interval (CI)] = 1.15 [1.14–1.17]} versus the weighted MSM [IRR (95% CI) = 0.79 (0.77–0.81)], but was consistently associated with a lower risk of serious infection in both the unweighted Cox model [IRR (95% CI] = 0.79 (0.78–0.81)) and the weighted MSM [IRR (95% CI) = 0.71 (0.68–0.75)]. Similar results were found when current and past treatments were simultaneously assessed. CONCLUSIONS: The discrepancy of effect estimates for overall but not serious infection comparing unweighted models and MSM suggested analyses of composite outcomes with a wide range of disease severity may be more susceptible to time-varying confounding. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00198-017-4129-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5624978
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-56249782017-10-16 Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data Xue, F. Goli, V. Petraro, P. McMullan, T. Sprafka, J. M. Tchetgen Tchetgen, E. J. Osteoporos Int Original Article SUMMARY: Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be causing time-varying confounding. BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model versus the weighted MSM. The discrepancy of effect estimates for overall infection in the MSM suggested there may be time-varying confounding. INTRODUCTION: Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be affected by prior treatment and confound the subsequent treatment effect, causing time-varying confounding. METHODS: In a US insurance database, the association between joint treatment of bisphosphonates (BP) and other OP medication and the incidence of infections among postmenopausal women was assessed using a marginal structural model (MSM). Stabilized weights were estimated by modeling treatment and censoring processes conditioning on past treatment, and baseline and time-varying covariates. RESULTS: BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model {incidence rate ratio [IRR] [95% confidence interval (CI)] = 1.15 [1.14–1.17]} versus the weighted MSM [IRR (95% CI) = 0.79 (0.77–0.81)], but was consistently associated with a lower risk of serious infection in both the unweighted Cox model [IRR (95% CI] = 0.79 (0.78–0.81)) and the weighted MSM [IRR (95% CI) = 0.71 (0.68–0.75)]. Similar results were found when current and past treatments were simultaneously assessed. CONCLUSIONS: The discrepancy of effect estimates for overall but not serious infection comparing unweighted models and MSM suggested analyses of composite outcomes with a wide range of disease severity may be more susceptible to time-varying confounding. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00198-017-4129-6) contains supplementary material, which is available to authorized users. Springer London 2017-07-06 2017 /pmc/articles/PMC5624978/ /pubmed/28685279 http://dx.doi.org/10.1007/s00198-017-4129-6 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Xue, F.
Goli, V.
Petraro, P.
McMullan, T.
Sprafka, J. M.
Tchetgen Tchetgen, E. J.
Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title_full Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title_fullStr Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title_full_unstemmed Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title_short Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
title_sort marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624978/
https://www.ncbi.nlm.nih.gov/pubmed/28685279
http://dx.doi.org/10.1007/s00198-017-4129-6
work_keys_str_mv AT xuef marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata
AT goliv marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata
AT petrarop marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata
AT mcmullant marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata
AT sprafkajm marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata
AT tchetgentchetgenej marginalstructuralmodeltoevaluatetheassociationbetweencumulativeosteoporosismedicationandinfectionusingclaimsdata